Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Published:2020-02 Issue:2 Volume:7 Page:e100-e111
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Walker Irwin,Panzarella Tony,Couban Stephen,Couture Felix,Devins Gerald,Elemary Mohamed,Gallagher Geneviève,Kerr Holly,Kuruvilla John,Lee Stephanie J,Moore John,Nevill Thomas,Popradi Gizelle,Roy Jean,Schultz Kirk R,Szwajcer David,Toze Cynthia,Foley Ronan

Funder

Amgen

Takeda Pharmaceutical Company

Sanofi

Canadian Institutes of Health Research

Pfizer

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease;Lee;Biol Blood Marrow Transplant,2018

2. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research;Arai;Biol Blood Marrow Transplant,2015

3. Prospective, randomized, double-blind, phase III clinical trial of anti-t-lymphocyte globulin to assess impact on chronic graft-versus-Host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation;Soiffer;J Clin Oncol,2017

4. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial;Finke;Lancet Haematol,2017

5. GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD;Cells;2024-09-11

2. Unrelated umbilical cord blood transplantation using a noval conditioning regimen for small month-old infants with rare non-malignant disorders;2024-08-26

3. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15

4. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes;Viruses;2024-08-14

5. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Bone Marrow Transplantation;2024-04-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3